Our markets and distributors

Bahrain

Screening population:
428,244
Distributor:
Renovate Biologicals
Appointed 2025
Cervical cancer is the 8th most frequent cancer among women in Bahrain and the 8th most frequent cancer among women between 15 and 44 years of age.
Bangladesh

Screening population:
58,960,050
Distributor:
Xerox Medica Ltd
Cervical cancer is the second most common cancer among women in Bangladesh, accounting for about 12% to 13.3% of all female cancer cases. High mortality in Bangladesh is largely tied to late detection and limited specialized management.
Belgium

Screening population:
3,736,891
Distributor:
Renovate Biologicals
Appointed 2025
Cervical cancer is the 13th most frequent cancer among women in Belgium and the 4th most frequent cancer among women between 15 and 44 years of age.
Cambodia

Screening population:
5,760,017
Distributor:
Gorton Health Service Pty Ltd
Appointed 2019
Cervical cancer is the 2nd most common cancer for women in Cambodia.
Central Asia

Screening population:
13,000,000
Distributor:
IMS
Appointed 2025
Sales to Kazakhstan, Belarus, Kyrgyzstan and Armenia, to both private and public health systems are to follow product registration, supported by TruScreen’s inclusion in the Russian Obstetricians and Gynaecologists guideline in early 2025. This is a key reference guide for all former Soviet republics.
China

Screening population:
472,394,210
Distributor:
Siweixiangtai Tech Ltd Co.
Appointed 2014
China is TruScreen’s most established market. It accounts for over 20% of cervical cancer diagnoses worldwide. TruScreen has been involved in several large-scale evaluation trials with public governing bodies, screening over 18,000 women.
Colombia

Screening population:
18,661,303
Distributor:
Sunbird
Cervical cancer is the second most common cancer in incidence among women and remains a leading cause of cancer-related death or disease burden in the country.
Côte d'Ivoire

Screening population:
8,812,363
Distributor:
Zerocancer Professional Consult Limited
Cervical cancer is the deadliest and second most common cancer among women in Côte d'Ivoire, and WHO predicts an increase of 47.5% in cervical cancer related mortality rate by 2040. Around 70% of all cases are identified at an advanced stage, which significantly lowers survival outcomes.
Denmark

Screening population:
1,877,887
Distributor:
Renovate Biologicals
Appointed 2025
Cervical cancer is the 11th most frequent cancer among women in Denmark and the 3rd most frequent cancer among women between 15 and 44 years of age.
Eswatini

Screening population:
394,631
Finland

Screening population:
1,692,185
Distributor:
Renovate Biologicals
Appointed 2025
Cervical cancer is the 15th most frequent cancer among women in Finland and the 4th most frequent cancer among women between 15 and 44 years of age.
France

Screening population:
21,196,604
Distributor:
Renovate Biologicals
Appointed 2025
Cervical cancer is the 12th most frequent cancer among women in France and the 4th most frequent cancer among women between 15 and 44 years of age.
Germany

Screening population:
25,843,667
Distributor:
Renovate Biologicals
Appointed 2025
Cervical cancer is the 14th most frequent cancer among women in Germany and the 3rd most frequent cancer among women between 15 and 44 years of age.
Ghana

Screening population:
10,438,740
Distributor:
Zerocancer Professional Consult Limited
Cervical cancer is the second most frequent cancer among women in Ghana. Over 3,000 women are diagnosed with cervical cancer in Ghana each year, and more than half of those diagnosed die from the disease.
India

Screening population:
477,104,306
Distributor:
Renovate Biologicals Pvt Ltd
Appointed 2025
Cervical cancer is the second most common cancer among women in India, despite being the fourth most common globally. One woman dies from cervical cancer every eight minutes in the country, making it a significant public health concern. In 2023 it was estimated that 123,907 women were diagnosed with cervical cancer and 77,348 died.
Indonesia

Screening population:
95,412,234
Distributor:
PT Mawar Mitra Medika
Appointed 2025

Cervical cancer ranks as the 2nd most frequent cancer among women in Indonesia. In 2018 TruScreen was granted approval, by Department Kesehatan RI, for use and sale in the country.
Iran

Screening population:
31,165,410
Distributor:
Renovate Biologicals
Appointed 2025
Cervical cancer is the 14th most frequent cancer among women in Iran and the 10th most frequent cancer among women between 15 and 44 years of age.
Iraq

Screening population:
13,790,327
Distributor:
Renovate Biologicals
Appointed 2025
Cervical cancer is the 15th most frequent cancer among women in Iraq and the 12th most frequent cancer among women between 15 and 44 years of age.
Italy

Screening population:
18,616,663
Distributor:
Chinni Oy Euro Asia SRL
Appointed 2026
Cervical cancer is the the 15th most frequent cancer among women in Italy and the 4th most frequent cancer among women between 15 and 44 years of age.
Jordan

Screening population:
3,589,846
Cervical cancer ranks as the 11th most frequent cancer among women in Jordan overall, and the 10th most frequent cancer among women aged 15 to 44. According to insights from the 2023 Jordan Population and Family Health Survey, only 16.4% of ever-married women have ever undergone cervical cancer screening (such as a Pap smear), leaving 83.6% unscreened.
Kuwait

Screening population:
1,397,344
Distributor:
Renovate Biologicals
Appointed 2025
Cervical cancer is the 3rd most common cancer in women aged 15 to 44 years in Kuwait.
Lebanon

Screening population:
1,911,432
Distributor:
Renovate Biologicals
Appointed 2025
Cervical cancer is the 10th most frequent cancer among women in Lebanon and the 8th most frequent cancer among women between 15 and 44 years of age.
Malaysia

Screening population:
11,761,748
Distributor:
Intega Pte Ltd
Appointed 2024
Cervical cancer is the 2nd most frequent cancer for women aged between 15 and 44 years in Malaysia, and the 3rd most common cancer for women overall in the country.
Mexico, Panama, Ecuador and Bolivia

Screening population:
52,271,615
Distributor:
Sunbird S.A. de C.V.
Appointed 2020
Mexico is TruScreen’s entry point into South America, with cervical cancer being the third most common cancer in women in the region. TruScreen has been present in Mexico since 2015. Sunbird is also working with authorities in Panama, Ecuador and Bolivia to identify opportunities.
Netherlands

Screening population:
5,765,126
Distributor:
Renovate Biologicals
Appointed 2025
Cervical cancer is the 12th most frequent cancer among women in Netherlands and the 3rd most frequent cancer among women between 15 and 44 years of age.
Nigeria

Screening population:
64,251,214
Distributor:
Zerocancer Professional Consult Limited
Cervical cancer is the second most common cancer and the second leading cause of cancer deaths among women in Nigeria, following breast cancer.
Oman

Screening population:
1,283,163
Distributor:
Renovate Biologicals
Appointed 2025
Cervical cancer is the 4th most frequent cancer among women in Oman and the 3rd most frequent cancer among women between 15 and 44 years of age.
Qatar

Screening population:
591,575
Distributor:
Renovate Biologicals
Appointed 2025
Cervical cancer is the 5th most frequent cancer among women in Qatar and the 3rd most frequent cancer among women between 15 and 44 years of age.
Romania

Screening population:
6,066,851
Distributor:
Chinni Oy Euro Asia SRL
Appointed 2026
Cervical cancer is the 3rd most frequent cancer among women in Romania and the 2nd most frequent cancer among women between 15 and 44 years of age.
Rwanda

Screening population:
4,320,219
Distributor:
Biotech Medical Supply Ltd (BMS)
Cervical cancer ranks as the 2nd most frequent cancer among women in Rwanda and the most frequent cancer among women between 15 and 44 years of age.
Saudi Arabia

Screening population:
9,343,496
Distributor:
Renovate Biologicals
Appointed 2025
Cervical cancer ranks as the 9th most frequent cancer among women in Saudi Arabia. More than 40% of cervical cancer cases are diagnosed at advanced stages due the absence of a routine cervical screening program.
Singapore

Screening population:
2,128,790
Distributor:
Intega Pte Ltd
Appointed 2024
Cervical cancer is the 11th most frequent cancer for women aged between 15 and 44 years in Singapore, and the 5th most common cancer for women overall in the country.
South Africa

Screening population:
21,982,447
Distributor:
Air
Appointed 2025
Cervical cancer is the 2nd most frequent cancer for women aged between 15 and 44 years in South Africa, and the most common cancer for women overall in the country.
Sri Lanka

Screening population:
7,392,361
Distributor:
Future Care
Cervical cancer is the 2nd most frequent cancer for women aged between 15 and 44 years in Sri Lanka, and the 4th most common cancer for women overall in the country.
Sweden

Screening population:
3,209,212
Distributor:
Renovate Biologicals
Appointed 2025
Cervical cancer is the 10th most frequent cancer among women in Sweden and the 3rd most frequent cancer among women between 15 and 44 years of age.
Thailand

Screening population:
25,414,634
Distributor:
Intega Pte Ltd
Appointed 2024
Cervical cancer is 2nd most prevalent cancer for women in Thailand.
Turkiye

Screening population:
28,914,621
Distributor:
Renovate Biologicals
Appointed 2025
Cervical cancer is the 12th most frequent cancer among women in Turkiye and the 5th most frequent cancer among women between 15 and 44 years of age.
United Arab Emirates

Screening population:
3,003,895
Distributor:
Renovate Biologicals
Appointed 2025
In United Arab Emirates, cervical cancer ranks as the 5th most frequent cancer among women and the 3rd most frequent cancer among women between 15 and 44 years of age.
United Kingdom

Screening population:
21,998,793
Distributor:
Renovate Biologicals
Appointed 2025
Cervical cancer is the 12th most frequent cancer among women in United Kingdom and the 2nd most frequent cancer among women between 15 and 44 years of age.
Uzbekistan

Screening population:
11,321,831
Distributor:
Albatros Health Care LLC
Cervical cancer ranks as the 2nd most common cancer for women in Uzbekistan, and 2nd most frequent cancer among women between 15 and 44 years of age. TruScreen is working directly with the Uzbek Ministry of Health on a 500 patient pilot screening program with planned province by province expansion.
Vietnam

Screening population:
34,610,177
Distributor:
Gorton Health Services (GHS)
Appointed 2016
Cervical cancer ranks as the 7th most common cancer for women in Vietnam. In 2020, TruScreen received Ministry of Health approval for use in leading Hanoi Obstetrics and Gynaecology Hospital. In July 2025, a 260,000 patient Public Screening Program launched in Ho Chin Minh City.
Yemen

Screening population:
11,306,057
Distributor:
Renovate Biologicals
Appointed 2025
Cervical cancer is the 12th most frequent cancer among women in Yemen and the 8th most frequent cancer among women between 15 and 44 years of age.
Zimbabwe

Screening population:
4,968,888
Distributor:
Southern Skies Medical Pty Ltd
Appointed 2018
Cervical cancer is the most common cancer among women in Zimbabwe. In 2018 TruScreen partnered with Zimbabwe’s National Aids Council (NAC) for a national cervical screening project.